期刊文献+

IL-2淋巴间隙给药对宫颈癌荷瘤机体特异性T细胞免疫功能的影响 被引量:6

The T Mediated Immunofunction of Cancer-bearing Mice Treatment of IL-2 Though the Space Perilymphamatically
暂未订购
导出
摘要 目的 :通过宫颈癌小鼠爪垫注射IL - 2及 5 -Fu后检测T细胞功能 ,探讨淋巴间隙给药在肿瘤细胞因子生物治疗中的效应。方法 :传代培养的小鼠宫颈癌细胞 (U14 )接种于Balb/c小鼠的左腋部皮下 ,构建荷瘤小鼠动物模型。荷瘤小鼠随机分为IL - 2组、 5 -Fu、IL - 2 +5 -Fu组及生理盐水对照。治疗 10天后分离小鼠脾脏细胞检测CTL细胞杀伤活性、淋巴细胞转化及IL - 2产生情况。结果 :CTL活性分别为 :对照组 :17 6 3±3 75 % ;IL - 2组 :2 7 34± 6 15 % ;5 -Fu组 :19 6 2± 5 17% ;IL - 2 +5 -Fu组 :2 4 0 1± 6 2 3%。淋巴细胞转化指数分别为 :对照组 :0 94± 0 13;IL - 2组 :1 92± 0 2 1;5 -Fu组 :1 30± 0 18;IL - 2 +5Fu组 :1 78± 0 2 8;IL- 2活性分别为 :对照组 :8± 2 1;IL - 2组 :12± 2 2 ;5 -Fu组 :9± 2 5 ;5 -Fu +IL - 2组 :13± 3 2。结论 :宫颈荷瘤小鼠爪垫注射细胞因子能显著性提高荷瘤机体的特异性细胞免疫功能。 Objective:Assay the activity of T cell of cervix cancer-bearing mice who therapy by IL-2 or 5-Fu through the space perilymphamatically in this way to investigate the effection of IL-2 in the treatment of cancer through injecting them in the space perilymphamatically. Method: Constructed a cervix cancer-bearing BALB/C mice by transplanted U14 cell line. The cancer-bearing mice were divided into four groups. Treated by IL-2, 5-Fu,IL-2+5Fu or NS separately. Assay the NK and LAK activity of their spleen cells after 10 days of treatment. Result:The activations of CTL are: NS:17.63±3.75%; IL-2:27.34±6.15%; 5-Fu:19.62±5.17%;IL-2+5-Fu:24.01±6.23%.The lymphocyte transform indexes are, NS:0.94±0.13;IL-2:1.92±0.21;5-Fu:1.30±0.18;IL-2+5Fu:1.78±0.28;The activation of IL-2 are:NS:8±2.1;IL-2:12±2.2;5-Fu:9±2.5;5-Fu+IL-2:13±3.2.Conclusion:It can promote the function of T cell mediated immunofunction of cervix cancer bearing mice by injected IL-2 cytokine in the space perilymphamatically.
出处 《华西医学》 CAS 2004年第2期216-218,共3页 West China Medical Journal
关键词 IL-2 淋巴间隙给药 宫颈癌 荷瘤小鼠 特异性T细胞 免疫功能 生物治疗 IL-2 space of lymphamatically T cell mediated immunofunction cervix cancer
  • 相关文献

参考文献9

  • 1Fujita T, Tamura T, Yamada H, et al. Pharmacokinetics of mitomycin C (MMC) after intraperitoneal administration of MMC-gelatin gel and its anti-tumor effects against sarcoma-180 bearing mice[J].J Drug Target. 1997;4(5):289-96.
  • 2Conomus JS,Hoban M,Lee JD,et al. Production of tumor necrosis factor alpha and interferon gamma in interleukine-2 treated melanoma patients:correlation with clinical toxicity[J].Cancer Immunol Immunother,1991,34:49-52.
  • 3Oldham RK.Biologicals and biological response modifiers:fourth modality of cancer treatment[J]. Cancer Treat Rep. 1984 Jan;68(1):221-32.
  • 41 Alan F,Holmer.The century of biology begins with 369 biotechnology medicines in testing for more than 200 diseases[M].New medicine in development biotechnology,2000:1.
  • 5Frucht DM. IL-23:a cytokine that acts on memory T cells[J].Sci STKE. 2002 Jan 8;2002(114):PE1. Review.
  • 6Alan F.Holmer.The century of biology begins with 369 biotechnology medicines in testing for more than 200 disease[M]. New medicine in development Biotechnology,2000:1-5.
  • 7Ettinghausen SE,Moore JG,White DE,et al.Hematalogic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukine-2 in cancer patients[J].Blood,1987,69(6):1654-1660.
  • 8Lee RE,Lotze HM,Skibber JM,et al. Cardiorespiratory effects of immunotherapy with interleukine-2[J]. J Clin Oncol,1989,7(1):7-20.
  • 9Yoshikawa H. Advanced Drug Deliv Rev,1997,28(2):239-251.

同被引文献51

  • 1吴伟,刘联斌,周茂华.放化疗对鼻咽癌患者淋巴细胞亚群影响的观察[J].中华肿瘤防治杂志,2013,20(2):129-132. 被引量:19
  • 2武燕.宫颈癌患者Th1/Th2细胞因子表达水平的研究[J].肿瘤研究与临床,2006,18(5):310-312. 被引量:24
  • 3常昕莹,唐军民,诸雪峻,唐岩,罗天霞,李枫.人宫颈上皮内瘤变和浸润癌组织中树突状细胞及T细胞的免疫组织化学定量分析[J].解剖学报,2007,38(1):75-80. 被引量:4
  • 4Stehlin JS.Hyperthermia perfusion of extremities for melanoma and soft tissue sarcoma.Recent Results Cancer Res 1997;59(2):171-85
  • 5孙卫民,王惠琴.细胞因子研究方法学.北京:人民卫生出版社,2000.21-23.
  • 6Hirose K, Hakozaki M, Nyunoya Y, et al . Che2 mokine gene transfection into tumor cells reduced tumorigenicity in nude mice in association with neutrophilic infiltration. Br J Cancer, 1995,72(3) : 708-714.
  • 7Tabata T. Th2 subset dominance among peripheral blood Tlymphocytes in patients with digestive cancers[J]. Am J Surg,1999, 177(3):203-208.
  • 8Hess S,Smola H. Sandaradura DS. Loss of IL-6 receptor ex-pression in cervical carcinoma cells inhibits autocrine IL-6 stim-ulation: abrogation of constitutive monocte chemoattractantprotein-1 production [ J ]. J Immunol,2000, 165 (4):1939-1948.
  • 9Yoshimura T,Matsushima K, Oppenheim J, et al.Neutrophilchemotactic factor produced by lipolysaccharide(LPS) stimula-ted human blood mononuclear leukocytes: partial characteriza-tion and separation from interleukin 1 (IL,-1)[J].J Immunol,1987,139(3);788-793.
  • 10Zhang JP, Yang J, Xu J,et al. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellularcarcinoma patients[J]. J Hepatol, 2009,50(5) :980-989.

引证文献6

二级引证文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部